Elsevier

Ophthalmology

Volume 113, Issue 9, September 2006, Pages 1508.e1-1508.e25
Ophthalmology

Original Article
Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration

Study results presented in part at: Association for Research in Vision and Ophthalmology Annual Meeting, May 2005, Fort Lauderdale, Florida.
https://doi.org/10.1016/j.ophtha.2006.02.064Get rights and content

Objective

To evaluate the efficacy of a second year of pegaptanib sodium therapy in patients with neovascular age-related macular degeneration (AMD).

Design

Two concurrent, multicenter, randomized, double-masked, sham-controlled studies (V.I.S.I.O.N. [Vascular Endothelial Growth Factor Inhibition Study in Ocular Neovascularization] trials).

Participants

Patients with all angiographic neovascular lesion compositions of AMD were enrolled. In combined analyses, 88% (1053/1190) were re-randomized at week 54, and 89% (941/1053) were assessed at week 102.

Interventions

At week 54, those initially assigned to pegaptanib were re-randomized (1:1) to continue or discontinue therapy for 48 more weeks (8 injections). Those initially assigned to sham were re-randomized to continue sham, discontinue sham, or receive 1 of 3 pegaptanib doses.

Main Outcome Measures

Mean change in visual acuity (VA) over time and mean change in the standardized area under the curve of VA and proportions of patients experiencing a loss of ≥15 letters from week 54 to week 102; losing <15 letters (responders) from baseline to week 102; gaining ≥0, ≥1, ≥2, and ≥3 lines of VA; and progressing to legal blindness (20/200 or worse).

Results

In combined analysis, mean VA was maintained in patients continuing with 0.3-mg pegaptanib compared with those discontinuing therapy or receiving usual care. In patients who continued pegaptanib, the proportion who lost >15 letters from baseline in the period from week 54 to week 102 was half (7%) that of patients who discontinued pegaptanib or remained on usual care (14% for each). Kaplan–Meier analysis showed that patients continuing 0.3-mg pegaptanib for a second year were less likely to lose ≥15 letters than those re-randomized to discontinue after 1 year (P<0.05). The proportion of patients gaining vision was higher for those assigned to 2 years of 0.3-mg pegaptanib than receiving usual care. Progression to legal blindness was reduced for patients continuing 0.3-mg pegaptanib for 2 years.

Conclusions

Continuing visual benefit was observed in patients who were randomized to receive therapy with pegaptanib in year 2 of the V.I.S.I.O.N. trials when compared with 2 years’ usual care or cessation of therapy at year 1.

Section snippets

Study Design

Two concurrent, randomized, double-masked, sham-controlled dose-ranging studies (studies 1003 and 1004) enrolled patients at sites in the U.S., Canada, Europe, Israel, Australia, and South America. Institutional review board/ethics committee approval was obtained at each participating center. Eligibility criteria ensured the inclusion of patients with a broad range of visual acuity (VA) and neovascular AMD characteristics.32 In brief, ≥50-year-old patients with subfoveal choroidal

Patient Disposition

Figure 1 illustrates randomization and re-randomization at baseline and week 54 and patient flow. Eighty-eight percent (1053/1190) of patients who received at least 1 treatment were re-randomized at week 54; 89% (941/1053) of patients re-randomized at week 54 were assessed at week 102, and percentages were similar across study arms. The primary reason for patient withdrawal before re-randomization was patient request; less frequent reasons included protocol deviation and loss to follow-up. Note

Discussion

The wide eligibility criteria in the V.I.S.I.O.N. trials permitted enrollment of a diverse mix of neovascular AMD presentations. Specifically, occult-only or any combination of occult and classic angiographic lesion compositions was eligible. Furthermore, highly aggressive lesions with up to 6 disc areas of hemorrhage as well as more chronic lesions with up to 25% scarring and fibrosis were eligible. To avoid enrollment of totally quiescent or involuted occult lesions, documented evidence of a

References (39)

  • S. Resnikoff et al.

    Global data on visual impairment in the year 2002

    Bull World Health Organ

    (2004)
  • C.G. Owen et al.

    How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

    Br J Ophthalmol

    (2003)
  • Macula Vision Research Foundation. Macular degeneration 101. You should know. Macular degeneration as a public health...
  • Vision problems in the U.S. Prevalence of adult vision impairment and age-related eye disease in America

    (2002)
  • P.M. Hart et al.

    Visual outcomes in the subfoveal radiotherapy studya randomized controlled trial of teletherapy for age-related macular degeneration

    Arch Ophthalmol

    (2002)
  • Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degenerationtwo-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2

    Am J Ophthalmol

    (2001)
  • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfintwo-year results of 2 randomized clinical trials—TAP report 2

    Arch Ophthalmol

    (2001)
  • D.W. Leung et al.

    Vascular endothelial growth factor is a secreted angiogenic mitogen

    Science

    (1989)
  • T. Alon et al.

    Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

    Nat Med

    (1995)
  • Cited by (183)

    • Nanotechnology in age-related macular degeneration

      2023, Nanotechnology in Ophthalmology
    • Age related macular degeneration 2020

      2021, Bulletin de l'Academie Nationale de Medecine
    • Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology

      2019, Ophthalmology
      Citation Excerpt :

      Treatment benefit was observed with intravitreal pegaptanib injection regardless of baseline VA and lesion size or angiographic subtype. In the VISION trial, 78% of patients never received PDT before enrollment in the VISION trial.36 On the basis of this trial, the FDA approved the intravitreal injection of 0.3 mg pegaptanib in 2004 as the first anti-VEGF therapy for neovascular AMD.19

    • Evolution of Intravitreal Therapy for Retinal Diseases—From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture

      2018, American Journal of Ophthalmology
      Citation Excerpt :

      Between 2001 and 2005, NX1838 became pegaptanib (Macugen) and rhuFab became ranibizumab (Lucentis). Eyetech completed 2 randomized clinical trials that established pegaptanib as modestly effective for slowing vision loss, but ineffective for improving vision in most patients.68,69 It was enough for FDA approval in December 2004 and the drug was launched in January 2005.

    View all citing articles on Scopus

    Manuscript no. 2005-1091.

    Study sponsored by Eyetech Pharmaceuticals, Inc., New York, New York, and Pfizer Inc., New York, New York.

    Correspondence and reprint requests to Usha Chakravarthy, MD, Centre for Vision Sciences, The Queen’s University of Belfast and The Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, United Kingdom. E-mail: [email protected].

    Members of the study group taking authorship responsibility for this article and who had complete access to the data needed for this report are listed in “Appendix I” along with their pertinent financial conflict-of-interest statements.

    View full text